This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C20 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the date of cancer registration) |
| B. Synonyms | Rectal cancer, Rectal adenocarcinoma, Rectal carcinoma |
| C. Adult onset | Very high — mainly in the 50s–70s; rectal cancer can be detected early by digital rectal examination |
| 1. History | Miles APR operation (1908), TME (Heald 1982), standardization of neoadjuvant CCRT, advances in preoperative radiotherapy and immunotherapy |
| 2. Causes | Diet (processed meat, red meat), obesity, physical inactivity, alcohol, smoking, inflammatory bowel disease, hereditary syndromes |
| 3. Genetics | APC, KRAS, TP53 and SMAD4 mutations, BRAF and MMR/MSI-H, Lynch, FAP and MAP; CMS classification |
| 4. General epidemiology | About 30–35% of colorectal cancers in Korea; about 9,000–10,000 cases per year; male predominance; increasing at age 50 and under |
| 5. Pathophysiology | Vogelstein multistep model, prolonged contact with solid stool in the rectum, carcinogenic features of the left colon; TME anatomy |
| 6. Symptoms | Bloody stools (fresh blood), change in bowel habits, sensation of incomplete evacuation, tenesmus, anal bleeding, mucus discharge, pelvic pain |
| 7. Signs | Digital rectal examination, proctoscopic tumor findings, pelvic MRI, CEA, anemia, signs of bladder or prostate invasion |
| 8. Screening | National screening (fecal occult blood test from age 50 → colonoscopy), digital rectal examination, surveillance endoscopy for Lynch and FAP |
| 9. Diagnosis | Proctoscopy + biopsy, pelvic MRI (CRM, T stage), CT, EUS, PET-CT, TNM (AJCC 8th edition) |
| 10. Treatment | Neoadjuvant CCRT → TME (LAR/APR), short-course radiotherapy, FOLFOX/FOLFIRI + bevacizumab or cetuximab, immunotherapy |
| 11. Prognosis | 5-year survival stage I 87–92%, stage II 70–80%, stage III 40–60%, stage IV 10–15%; risk of local recurrence |
| 12. Prevention | Participation in national screening, removal of adenomas, diet, exercise and weight management, Lynch and FAP surveillance, smoking cessation and limiting alcohol |
| 13. References | Heald RJ et al. Lancet 1982 and 9 other papers |
The history of rectal cancer has developed together with surgical technique. When Miles established abdominoperineal resection (APR) in 1908, curative resection of rectal cancer became possible. APR removes both the rectum and the anal sphincter and creates a permanent colostomy, and it remained the standard operation for rectal cancer for decades. In the 1970s–80s, advances in medical devices and anastomotic techniques led to the spread of low anterior resection (LAR), making preservation of the anal sphincter possible even for lower rectal cancer.
When Richard Heald proposed Total Mesorectal Excision (TME) in 1982, the paradigm of rectal cancer surgery changed. TME is a technique of sharply dissecting and completely removing the mesorectum that envelops the rectum; when this principle was followed, local recurrence rates dropped sharply to 5–8%. After Heald's research was published, rectal cancer surgeons worldwide adopted the TME technique, and rectal cancer outcomes improved markedly. In the 1980s–90s, clinical studies showed that preoperative radiotherapy or concurrent chemoradiotherapy (CCRT) reduces local recurrence, establishing the concept of neoadjuvant therapy.
In Korea, standard treatment guidelines for rectal cancer are continually updated, led by the Korean Society of Coloproctology. Recent clinical advances include the introduction of laparoscopic and robotic rectal resection, transanal minimally invasive surgery (TaTME), omission of surgery in complete clinical responders after neoadjuvant CCRT (Watch-and-Wait), and neoadjuvant immune checkpoint inhibitor therapy for MSI-H rectal cancer. Multidisciplinary collaboration (surgery, medical oncology, radiation oncology, radiology) is essential in rectal cancer treatment.
The risk factors for rectal cancer largely overlap with those for colon cancer, but the anatomic features of the rectum (prolonged retention of solid stool) are an additional factor that increases carcinogen contact time. Excessive intake of processed and red meat is strongly associated with rectal cancer risk, and IARC has classified processed meat as a Group 1 carcinogen. Carcinogens in processed meat (N-nitroso compounds, heme iron) remain in contact with the rectal mucosa for a long time and promote carcinogenesis. Lack of dietary fiber prolongs colonic transit time, increasing the duration of carcinogen exposure. Obesity raises rectal cancer risk through insulin resistance, elevated IGF-1 and low-grade chronic inflammation, and physical inactivity raises it independently.
Alcohol consumption causes DNA damage in the rectal mucosa through an alcohol metabolite (acetaldehyde), and there are reports that its association with rectal cancer is stronger than with colon cancer. Smoking increases rectal cancer risk about 1.5–2-fold. Ulcerative colitis, in cases of pancolitis, also includes a risk of rectal cancer, and the risk is greater with longer disease duration and more extensive involvement. Prior radiotherapy (pelvic radiation) is a rare cause of secondary rectal cancer. Diabetes raises rectal cancer risk through insulin resistance.
Hereditary predisposition: Lynch syndrome increases cancer risk throughout the colon, but rectal cancer accounts for a somewhat lower proportion than colon cancer. In FAP (APC mutation), adenomatous polyposis followed by malignant change also occurs in the rectum, and even after prophylactic colectomy, cancer can arise in the residual rectal mucosa (when the rectum is preserved). MAP (MUTYH mutation) also increases rectal cancer risk.
The molecular genetics of rectal cancer is largely shared with colon cancer (C18), but there are some molecular differences. Conventional CIN pathway: the main somatic mutations are APC (about 70–80%), KRAS (about 40%), TP53 (about 50–60%), SMAD4 (about 10–15%) and PIK3CA (about 15%). MSI-H occurs in about 5–10% of rectal cancers, a lower rate than in colon cancer (about 15%). MSI-H is less common in rectal cancer because the BRAF V600E–related serrated pathway is more common in the right colon, while the CIN pathway is relatively predominant in rectal cancer. BRAF V600E is found in about 5–10% of rectal cancers.
In the CMS classification, CMS2 (canonical adenoma pathway, WNT and MYC activation, EGFR and HER2 upregulation) is the most common in rectal cancer, and CMS4 (mesenchymal type, TGF-β activation, poor prognosis) is also observed. The high proportion of CMS2 in rectal cancer is meaningful for predicting response to EGFR-targeted therapy (cetuximab, RAS wild-type). In Lynch syndrome–associated rectal cancer, germline MMR gene mutations are identified, and these tumors show an excellent response to immune checkpoint inhibitors.
Recently, in MSI-H rectal cancer, neoadjuvant immune checkpoint inhibitors (pembrolizumab, dostarlimab) have achieved a preoperative complete clinical response (cCR), forming a paradigm of applying a Watch-and-Wait strategy without surgery. The 2022 study by Cercek et al. (NEJM) drew attention by reporting that all 12 patients with MSI-H/dMMR rectal cancer achieved a complete clinical response after neoadjuvant treatment with dostarlimab alone. HER2-targeted therapy is being explored for HER2 amplification (about 2–5%). NTRK fusion (although very rare) is an indication for larotrectinib targeted therapy.
Rectal cancer (C20) accounts for about 30–35% of all colorectal cancers (C18–C20) in Korea, with an estimated 9,000–10,000 cases per year. It ranks among the most common cancers in both men and women. It occurs about 1.5–2 times more often in men than in women. By age, it is most common in the 60s–70s and increases sharply after age 50. However, early-onset rectal cancer under age 50 has recently been increasing, and the rise in young patients in their 30s–40s in particular is drawing attention.
Geographically, rectal cancer, like colon cancer, has a high incidence in cultures with a Westernized diet, and it is also increasing in East Asia, including Korea, with the Westernization of lifestyles. More than about 700,000 rectal cancers occur worldwide each year. The ratio of rectal to colon cancer varies by country, reflecting differences in diet and lifestyle. Lynch syndrome–associated rectal cancer accounts for about 1–3% of all rectal cancers and should be identified through genetic counseling and MSI testing. In FAP, the rectum is also a site at risk of adenomatous polyposis and malignant change, and surveillance of adenomas in the remaining rectal mucosa is needed after rectum-preserving surgery.
Thanks to the national colorectal cancer screening program, the early detection rate of rectal cancer in Korea is improving, and digital rectal examination in particular contributes to the early detection of lower rectal cancer. Local recurrence of rectal cancer remains an important clinical problem compared with other colon cancers, and standardization of neoadjuvant therapy and TME to address it remains important.
The pathogenesis of rectal cancer follows the same three molecular pathways as colon cancer, with the anatomic and physiologic features of the rectum acting as additional factors. The rectum is the final storage site for stool, so carcinogens, bile metabolites, secondary bile acids and other substances remain in contact with the rectal mucosa for a long time together with solidified stool. Secondary bile acids (deoxycholic acid, lithocholic acid) cause oxidative stress and DNA damage in rectal mucosal cells, increasing the risk of carcinogenesis. This is one reason why the rectum and sigmoid colon account for about 55–65% of all colorectal cancers.
The conventional CIN pathway (APC→KRAS→SMAD4→TP53) operates in about 65–70% of rectal cancers. The multistep progression — sustained activation of Wnt/β-catenin signaling due to loss of APC function → adenoma formation → accumulation of KRAS and TP53 mutations → invasive adenocarcinoma — takes place over 10–15 years. Endoscopic removal of rectal mucosal adenomas (especially serrated adenomas in the sigmoid–rectal region) can prevent cancer. Because the lower rectum lies within the pelvic space, tumors can easily invade surrounding structures (bladder, prostate, uterus, vagina, sacrum), which is an important anatomic consideration in planning surgery and radiotherapy.
The mesorectum is a fatty connective tissue structure enveloping the rectum that contains lymphatics, blood vessels and nerves, and TME is the principle of precisely excising this structure to radically remove the lymph node metastatic pathways. A positive circumferential resection margin (CRM) of the mesorectum is the strongest predictor of local recurrence. Immunosuppression in the tumor microenvironment (PD-L1 expression, Treg infiltration) contributes to rectal cancer progression, and in MSI-H rectal cancer an immune-activated tumor microenvironment is the basis of response to immune checkpoint inhibitors.
The symptoms of rectal cancer vary with tumor location (upper, middle or lower rectum), size and extent of invasion. The most characteristic symptom is bloody stools (rectal bleeding), with bright red blood mixed with stool or coating the stool surface during defecation. This is often mistaken for hemorrhoids, a major cause of diagnostic delay. In adults aged 40 and over, rectal bleeding must be evaluated by colonoscopy. Changes in bowel habits (constipation, diarrhea or alternating) occur as the tumor narrows the rectal lumen, accompanied by increased stool frequency, a reduced sense of complete evacuation and a sensation of incomplete evacuation.
Tenesmus is a symptom in which the rectum always feels full because of a rectal tumor, and it is especially characteristic of rectal cancer. Mucus discharge increases during defecation, and mucoid bloody stools (stool mixed with mucus and blood) appear. When the lower rectum or anal canal is invaded, anal pain and perianal pressure occur. Pelvic pain is a sign of advanced disease suggesting invasion of pelvic structures (sacrum, pelvic nerves). With bladder invasion, voiding dysfunction (frequency, hematuria, fecaluria) and a rectovesical fistula may occur. With uterine or vaginal invasion, vaginal bleeding or a rectovaginal fistula may develop. Weight loss and fatigue accompany the disease as progressive symptoms.
Rectal bleeding and changes in bowel habits are the most common early symptoms, but in some patients anemia is the only symptom. Fecal occult blood testing and colonoscopy for early detection are key to finding rectal cancer at the asymptomatic stage.
The most important physical examination in rectal cancer is digital rectal examination (DRE). Lower rectal tumors within 5–10 cm of the anal verge can be palpated directly by DRE, allowing assessment of tumor location, size, mobility (fixity) and sphincter involvement. Because DRE is noninvasive and provides immediate information, it should be performed in all patients with rectal bleeding. A fixed tumor suggests T4b (invasion of surrounding structures). Proctoscopy or rectal endoscopy determines the distance of the tumor from the anal verge, the proportion of the circumference involved and the mucosal appearance.
Contrast-enhanced pelvic MRI is the key imaging study for staging and treatment planning in rectal cancer. If the circumferential resection margin (CRM) is within 1 mm, it is judged CRM-positive (at risk) and becomes an indication for neoadjuvant therapy. The relationship with the peritoneal reflection, lymph nodes within the mesorectum and extramural vascular invasion (EMVI) are evaluated by MRI. Blood tests show elevated CEA (baseline and follow-up), anemia (chronic bleeding) and abnormal liver function (liver metastasis). Molecular markers such as MMR protein IHC (MSI-H status), RAS (KRAS, NRAS), BRAF V600E and HER2 status are important in determining the treatment course. Left supraclavicular lymphadenopathy (Virchow's node), hepatomegaly (liver metastasis) and ascites (peritoneal metastasis) are systemic signs of advanced disease.
Korea's national colorectal cancer screening program applies equally to rectal cancer screening. Men and women aged 50 and over undergo an annual iFOBT (immunochemical fecal occult blood test), and if positive, the entire large intestine including the rectum is evaluated by colonoscopy. The rectum is easily accessible endoscopically, and lower rectal tumors can also be found by digital rectal examination. Colonoscopy or proctoscopy should be performed in all adult patients with rectal bleeding. Digital rectal examination (DRE), when performed at annual routine checkups in primary care, contributes to early detection of lower rectal cancer.
Surveillance of high-risk groups: for Lynch syndrome, colonoscopy every 1–2 years from age 20–25; for FAP, annual colonoscopy from puberty (including proctoscopy after rectum-preserving surgery); for ulcerative colitis (pancolitis, 10 years or more), colonoscopy + random biopsies every 1–2 years; and with a family history (colorectal cancer in a first-degree relative), colonoscopy from age 40 or 10 years before the family member's age at onset is recommended. In rectal cancer, pelvic MRI is essential for accurate staging, so contrast-enhanced pelvic MRI should be performed immediately when rectal cancer is suspected or diagnosed. Flexible sigmoidoscopy can also evaluate the rectum and sigmoid colon, but colonoscopy is the standard in Korean national screening.
Rectal cancer is confirmed by proctoscopy (or colonoscopy) + tissue biopsy. After rectal cancer is diagnosed, contrast-enhanced pelvic MRI is essential. Using T2-weighted images, MRI evaluates the layer of rectal wall invasion, lymph nodes within the mesorectum, the CRM, the relationship with the peritoneal reflection, vascular invasion (EMVI) and invasion of adjacent organs. The exact T and N stage of the rectal cancer, CRM status and distance from the anal sphincter determine the surgical approach and the need for neoadjuvant therapy. CT (abdomen, chest, pelvis) is used to evaluate distant metastasis (liver, lungs, peritoneum) and lymph node metastasis. PET-CT is used as a complement for detecting distant metastasis when CT findings are unclear.
Endoscopic ultrasound (EUS) is useful for assessing T1–T2 stage (depth of rectal wall invasion) in lower rectal cancer and is used to determine the indication for endoscopic resection of T1 lesions. AJCC 8th edition TNM staging: T1 (mucosa to submucosa), T2 (muscularis propria), T3 (mesorectum, subserosal connective tissue), T4a (visceral peritoneum), T4b (adjacent organs). N1a (1 node), N1b (2–3 nodes), N1c (tumor deposit), N2a (4–6 nodes), N2b (7 or more nodes). M1a–c are the same as for colon cancer. After tissue biopsy, MMR protein IHC (or MSI PCR/NGS), RAS (KRAS, NRAS), BRAF V600E and HER2 testing is performed. MSI-H rectal cancer is an indication for neoadjuvant immunotherapy. The baseline CEA level must be recorded.
Treatment of rectal cancer is determined by stage, tumor location (distance to the anal verge), CRM status and molecular subtype. For low-risk rectal cancer with T1 submucosal invasion, endoscopic submucosal dissection (ESD) or transanal excision is possible. The standard treatment for stage II–III rectal cancer (T3–T4, N+) is neoadjuvant concurrent chemoradiotherapy (neoadjuvant CCRT: 45–50.4 Gy + capecitabine or 5-FU) followed by TME-based surgery. Surgery is performed 6–10 weeks after completion of neoadjuvant therapy. In patients who achieve a complete clinical response (cCR) after neoadjuvant CCRT, a Watch-and-Wait strategy (close follow-up without surgery) is applied selectively (based on the OPERA and OnCoRe studies).
The surgical approach is determined by the distance of the tumor from the anal verge. Low anterior resection (LAR) + TME is performed when the anal sphincter can be preserved, and abdominoperineal resection (APR) when the anal canal is invaded or sphincter function cannot be preserved, with creation of a permanent colostomy. Minimally invasive (laparoscopic, robotic) TME and transanal minimally invasive surgery (TaTME) are spreading. Adjuvant CCRT is given when postoperative pathology shows a positive CRM or extracapsular nodal extension. Adjuvant chemotherapy (FOLFOX or CAPOX) is recommended after surgery for stage III disease. For MSI-H/dMMR rectal cancer, an innovative study showed that neoadjuvant immune checkpoint inhibitor monotherapy (pembrolizumab, dostarlimab) leads to complete clinical response, raising the possibility of omitting surgery (Cercek et al., NEJM 2022). Treatment of metastatic (stage IV) rectal cancer follows the same principles as colon cancer (C18) (FOLFOX or FOLFIRI ± bevacizumab/cetuximab, pembrolizumab for MSI-H, BEACON for BRAF V600E).
The prognosis of rectal cancer is similar to that of colon cancer, but differs in the risk of local recurrence and in functional complications due to invasion of pelvic structures. 5-year survival by stage: stage I about 87–92%, IIA about 78–82%, IIB about 65–70%, IIIA about 75–80%, IIIB about 55–65%, IIIC about 35–45%, IV about 10–15%. The overall 5-year survival rate of colorectal cancer in Korea is 75–80%, and outcomes for rectal cancer are also steadily improving with early detection and standardization of TME.
Prognostic factors: a positive CRM (circumferential resection margin) is the strongest predictor of local recurrence and is predicted preoperatively by MRI. The completeness of TME (mesorectal grading: complete/nearly complete/incomplete) directly affects local recurrence. EMVI (vascular invasion) is also a poor prognostic factor. MSI-H rectal cancer responds excellently to immunotherapy and may achieve complete remission without surgery after neoadjuvant immunotherapy, offering the potential for a breakthrough in prognosis. Patients who achieve pCR (pathologic complete response) after neoadjuvant CCRT have a very good long-term prognosis. Both local recurrence in the pelvis and distant metastasis (liver, lungs) are important patterns of recurrence. For local recurrence, reoperation (pelvic exenteration), re-irradiation and systemic therapy are combined. Because post-treatment functional complications (low anterior resection syndrome, bowel dysfunction, sexual dysfunction, voiding dysfunction) significantly affect quality of life, rehabilitation is needed.
The key to rectal cancer prevention is participation in national colorectal cancer screening. From age 50, an annual fecal occult blood test is performed; if positive, the entire large intestine including the rectum is evaluated by colonoscopy, and any adenomas found are resected endoscopically at once. Because the rectum is easily accessible endoscopically and lower rectal lesions can also be found by digital rectal examination, it is important to include DRE in routine checkups. Adults aged 40 and over with rectal bleeding, changes in bowel habits or a sensation of incomplete evacuation should promptly undergo proctoscopic or colonoscopic evaluation.
Dietary prevention: minimizing intake of processed and red meat and a diet rich in dietary fiber (vegetables, fruit, whole grains, legumes) are recommended. Dietary fiber shortens colonic transit time, reducing carcinogen contact time. Calcium and vitamin D supplementation is also associated with a reduced risk of rectal adenoma and cancer. Regular physical activity, preventing obesity, smoking cessation and limiting alcohol are supporting preventive measures. In genetically high-risk groups with Lynch syndrome, FAP or MAP, early genetic counseling, surveillance endoscopy and, if needed, prophylactic surgery (FAP: total colectomy) are central to prevention. There is evidence that aspirin lowers rectal cancer risk, but general preventive use is not recommended; in Lynch syndrome, aspirin 600 mg/day is being studied based on the CaPP2 study. Considering the increase in rectal cancer at younger ages (50 and under), screening before age 40 is recommended for those with a family history or symptoms.